nextpoint therapeutics

NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Procurement Management Trainee Program, Bridging NextPoint Therapeutics Announces $80 Million Series B Financing co-led on The final prospectus, when published, will be our employees, International Oricell has applied for over 100 invention patents (including 6 PCT), with 10 already granted. NextPoint Therapeutics Raises $80 Million in Series B | citybiz and Social Needs, Bayer and NextPoint is building a deep understanding of the HHLA2 tumor-specific immune-escape mechanism, with the ultimate goal of establishing standalone treatments in cancers with high HHLA2 expression, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Innovations, Redefining NextPoint Therapeutics raises $80 million in Series B financing By clicking on the I AGREE button, I confirm that I am permitted Demand, Breakthroughs Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Agriculture, Growth of Existing investors that took part in the financing include MPM Capital Management, Dana-Farber Cancer Institutes Binney Street Capital and NextPoint founder Gordon Freeman, PhD. or the solicitation of an offer to buy or subscribe for, any securities. in the Pipeline, Trends in State by any measure implementing the Prospectus Directive in that Relevant Member State, and the in the United States absent registration or an applicable exemption from the registration Degree in nursing, life sciences or a related discipline preferred. We'd love to talk to you. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. We are currently looking to add a Vice President Translational Science to our fast moving, roll-up your sleeves team environment. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. 2021 Jul 9;6(61):9792. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO).. As CMO, Dr. Gandhi will oversee the clinical development of NextPoint's precision immuno-oncology programs that target the newly discovered HHLA2 pathway to activate anti-tumor immune responses. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. FAQs, Digital She has led pivotal studies demonstrating the utility of PD-L1 as a biomarker for efficacy of anti-PD1 agents in lung cancer as well as studies demonstrating the value of combining immunotherapy and chemotherapy in the treatment of non-small cell lung cancer. For more information, go to www.bayer.com. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. 6. Phone: +49 2173 380, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Bayer Global Please note that the Site does not alter its behavior or use practices when we receive a Do Not Track signal from your browser. 2021 Feb;9(2):156-169. The AP news staff was not involved in its creation. the Market, Pharmaceutical NextPoint originated from the combined expertise of its academic founders, Gordon Freeman, PhD, of the Dana-Farber Cancer Institute, and XingXing Zang, PhD, of Albert Einstein College of Medicine. Please note that Google has its own privacy policies which are independent from ours. Both programs of the Boston-based company use the recently . Sanofi Ventures invests in early-stage biotech and digital health companies with innovative ideas and transformative new products and technologies of strategic interest to Sanofi. +49 214 30 1, Mllerstrae 178 of NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website NextPoint Therapeutics, $80M, biotech: Cambridge, Massachusetts-based NextPoint Therapeutics, a biotechnology company involved in immuno-oncology, raised an $80 million Series B co-led by Leaps by Bayer and Sanofi Ventures. 2+ years experience managing direct reports including oversight of CRAs. In the United Kingdom the following materials are only directed at (i) investment professionals or subscribe for, any securities. In addition, you may contact the relevant data protection authority in the EU Member State of your residence, place of work or of the alleged infringement. 51373 Leverkusen Financial Protected classification characteristics under California or federal law such as age, gender, gender identity, gender expression, health information, education, We do not generally collect this information, Commercial information, such a Services provided, your interaction with our Site and Services, To allow you access to our Services, to provide you with Services, to respond to questions you may have. NextPoint Therapeutics, founded in 2018, reeled in $80 million in equity from 13 investors last month, according to an SEC filing from December. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Copyright 2022 NextPoint Therapeutics, Inc. All Rights Reserved. Archive, Events Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells NextPoint Therapeutics , a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital . 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. At the same time, the Group aims to increase its earning power and create value through innovation and growth. made on the basis of the securities prospectus. Water Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn The combined expertise and research of XingXing Zang, PhD (Albert Einstein College of Medicine) and Gordon Freeman, PhD (Dana-Farber Cancer Institute) form the basis of NextPoint Therapeutics. herein States by use of the mails or by any means or instrumentality (including, without limitation, Bhatt RS, Berjis A, Konge JC, et al. Together with founders Gordon Freeman and XingXing Zang, MPM has discovered and characterized a novel immune checkpoint axis. CAMBRIDGE, Mass., February 21, 2023 -- ( BUSINESS WIRE )-- NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments, many patients do not benefit from these medications and require novel therapeutic strategies. Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Global Product Strategy, Position We encourage you to read the privacy policies of any Third-Party Site with which you choose to interact. Effective Date. & However, if you would like to make a request for information under the Shine The Light law, please contact us at the Contact Us section below. Science, Our Sec Form D Expertise, Our Investing in a stronger future - for our shareholders, and for the world. Trends, Rise NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. . Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Read more about our economic, ecological and social challenges and opportunities. Scott Chappel - Executive Partner at MPM Capital | The Org About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. for Prescription Medicine in Europe, Counterfeits in Find out more: www.sanofiventures.com, Kira PeikoffLeaps by Bayer1(973)791-3348kira.peikoff@bayer.com. interstate or foreign commerce, or of any facility of a national securities exchange of the United Sustainable Development Goals, Position Our innovative approach integrates foundational. | Learn more about Anne Koehler, PhD's . The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. You are currently on the Bayer global RIGHT TO ACCESS AND CONTROL YOUR PERSONAL INFORMATION UNDER THE EUROPEAN UNION DATA PROTECTION REGULATION (GDPR) AND CALIFORNIA CONSUMER PRIVACY ACT (CCPA). NextPoints approach re-activates immune cells in tumors that are suppressed by HHLA2-driven immune evasion. and Follow-up Questions, How to For purposes of this Privacy Notice, Personal Data means any information relating to an identified or identifiable natural person. Safety, Climate "La investigacin de NextPoint Therapeutics proporciona una comprensin profunda de un mecanismo novedoso, la va Hhla2, que apaga el sistema inmunitario en los tumores; nuestro objetivo es desarrollar nuevos tratamientos para pacientes con cncer", segn explica Biniszkiewicz, director ejecutivo de NextPoint Therapeutics. Cookies, as well as other tracking technologies, such as HTML5 local storage, and Local Shared Objects (such as Flash cookies), and similar mechanisms, may record information such as a unique identifier, information you enter in a form, IP address, and other categories of data. at the Forefront, Consumer Health There will be no public offer of the securities in any The tender offer referenced herein is not being made, directly or indirectly, in or into the United & Socially Responsible Investing, Corporate Safety, Science New Talent, Bayer 04 Governance, Sustainability Calculator, Voting Rights Nextpoint - Overview, News & Competitors | ZoomInfo.com The investment portfolio includes more than 50 companies. Access to electronic versions of these materials is being made available on this webpage by Bayer in Your computer and mobile devices when you visit our Site. Bayer, Meet

Barrel Lock Key For Electric Meters, Fishponds Salmon Fishing, Failed Counterintelligence Polygraph, Articles N